24 November 2023 · Patients with mitochondrial variants have an increased risk of deafness with gentamicin, amikacin, tobramycin and neomycin. Guidance on testing is provided.

11 August 2022 · Amikacin products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration